Elemene plus standard therapy versus standard therapy alone
Part of Cancer clinical trials.
This Phase 2 trial studies whether adding Elemene to the usual treatment for newly diagnosed glioblastoma works better than standard treatment alone. It may help shrink the tumor for longer and improve outcomes, depending on how your brain tumor responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of glioblastoma in the brain (not elsewhere), and it is IDH-wildtype grade 4
- You are an adult under 70 years old
- You can do daily activities at a moderate level (Karnofsky score 60 or higher)
- Your expected survival is at least 12 weeks, and you can attend all treatment and follow-up visits
- Blood tests, liver tests, kidney tests, and blood-clotting tests must be in allowed ranges
- You must not have had prior treatment for glioblastoma (no chemo, radiation, or prior surgery for it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.